GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » Cash Flow from Financing

Kuros Biosciences (XSWX:KURN) Cash Flow from Financing : CHF-0.17 Mil (TTM As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Kuros Biosciences Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Kuros Biosciences paid CHF0.00 Mil more to buy back shares than it received from issuing new shares. It received CHF0.00 Mil from issuing more debt. It paid CHF0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received CHF0.00 Mil from paying cash dividends to shareholders. It received CHF0.50 Mil on other financial activities. In all, Kuros Biosciences earned CHF0.50 Mil on financial activities for the six months ended in Dec. 2023.


Kuros Biosciences Cash Flow from Financing Historical Data

The historical data trend for Kuros Biosciences's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences Cash Flow from Financing Chart

Kuros Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.13 17.08 6.08 3.22 -0.17

Kuros Biosciences Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.23 -0.17 3.39 -0.31 0.14

Kuros Biosciences Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Kuros Biosciences's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Kuros Biosciences's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-0.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kuros Biosciences  (XSWX:KURN) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Kuros Biosciences's issuance of stock for the six months ended in Dec. 2023 was CHF0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Kuros Biosciences's repurchase of stock for the six months ended in Dec. 2023 was CHF0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Kuros Biosciences's net issuance of debt for the six months ended in Dec. 2023 was CHF0.00 Mil. Kuros Biosciences received CHF0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Kuros Biosciences's net issuance of preferred for the six months ended in Dec. 2023 was CHF0.00 Mil. Kuros Biosciences paid CHF0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Kuros Biosciences's cash flow for dividends for the six months ended in Dec. 2023 was CHF0.00 Mil. Kuros Biosciences received CHF0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Kuros Biosciences's other financing for the six months ended in Dec. 2023 was CHF0.50 Mil. Kuros Biosciences received CHF0.50 Mil on other financial activities.


Kuros Biosciences Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Kuros Biosciences (XSWX:KURN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences (XSWX:KURN) Headlines

No Headlines